Prognostic value of neutrophil-to-lymphocyte ratio in end-stage liver disease: A meta-analysis

Table 2 Subgroup analyses

	Number of subgroup data from studies	Effect size	95%CI	I2	Q between subgoup
Univariate HR
Mean age
> 50	9	1.072	1.043-1.101	85.63c	0.492
≤ 50	3	1.056	1.016-1.097	92.65c
Study location
Not Asian	6	1.049	1.018-1.082	63.92a	2.168
Asian	8	1.082	1.054-1.110	91.32c
Population
AD	8	1.076	1.044-1.110	85.60c	0.376
ACLF	6	1.062	1.032-1.093	92.03c
Primary outcome
≤ 30 mortality	5	1.097	1.057-1.139	80.06c	2.852
Long term mortality	9	1.057	1.034-1.080	90.95c
Etiology
HBV	8	1.082	1.054-1.110	91.95c	2.168
Mixed	6	1.049	1.018-1.082	63.92a
Multivariate HR
Mean age
> 50	12	1.082	1.051-1.113	90.10c	0.621
≤ 50	2	1.052	0.986-1.121	83.28b
Study location
Not Asian	6	1.030	1.000-1.061	70.153b	7.728b
Asian	11	1.087	1.061-1.113	87.451c
Population
AD	11	1.046	1.038-1.054	91.00c	3.472
ACLF	6	1.031	1.022-1.040	82.00c
Mortality
≤ 30 mortality	6	1.087	1.044-1.131	77.08c	1.297
Long term mortality	11	1.058	1.033-1.083	91.38c
Etiology
HBV	7	1.069	1.030-1.110	78.04c	0.864
Mixed	10	1.065	1.036-1.095	92.38c
Univariate OR
Mean age
> 50	4	1.323	1.077-1.625	78.80b	0.036
≤ 50	5	1.289	1.080-1.538	85.73c
Population
AD	4	1.329	1.058-1.669	78.80b	0.095
ACLF	7	1.388	1.179-1.634	92.12c
Mortality
≤ 30 mortality	3	1.329	1.127-1.567	87.61b	0.301
Long term mortality	7	1.256	1.117-1.412	93.79c
Etiology
HBV	8	1.375	1.247-1.515	90.93c	3.558
Mixed	4	1.166	1.013-1.081	76.32b

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

AD: Acute decompensation; ACLF: acute-on-chronic liver failure; HR: Hazard ratios; HBV: Hepatitis B virus.